'+
'| • '+heading+' |
| '+
''+
' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('| 4/30 - 4:31 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 | \n'); } if (allow) { document.write('
| 4/22 - 7:14 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Reacts to U.S. Supreme Court\'s Denial of its Petition in HETLIOZ®\; ANDA Litigation | \n'); } if (allow) { document.write('
| 4/17 - 10:22 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan | \n'); } if (allow) { document.write('
| 4/17 - 9:11 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak | \n'); } if (allow) { document.write('
| 4/17 - 6:30 AM \; \; | \n'); } if (allow) { document.write('Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash | \n'); } if (allow) { document.write('
| 4/2 - 6:11 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals\' Fanapt®\; (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder | \n'); } if (allow) { document.write('
| 3/27 - 7:54 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA | \n'); } if (allow) { document.write('
| 3/25 - 3:46 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA | \n'); } if (allow) { document.write('
| 3/19 - 6:06 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA | \n'); } if (allow) { document.write('
| 3/11 - 7:56 PM \; \; | \n'); } if (allow) { document.write('SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA | \n'); } if (allow) { document.write('
| 3/6 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ®\; in the Treatment of Insomnia | \n'); } if (allow) { document.write('
| 2/7 - 4:03 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results | \n'); } if (allow) { document.write('
| 2/5 - 8:01 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ®\; in the Treatment of Insomnia | \n'); } if (allow) { document.write('
| 1/31 - 4:31 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024 | \n'); } if (allow) { document.write('
| 1/31 - 9:06 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis | \n'); } if (allow) { document.write('
| 1/30 - 12:36 PM \; \; | \n'); } if (allow) { document.write('Court Orders FDA to Resolve Vanda Pharmaceuticals\' Jet Lag Hearing Request by March 5, 2024 | \n'); } if (allow) { document.write('
| 1/29 - 7:01 PM \; \; | \n'); } if (allow) { document.write('Court Orders FDA to Resolve Vanda Pharmaceuticals\' Jet Lag Hearing Request by March 5, 2024 | \n'); } if (allow) { document.write('
| 1/25 - 10:07 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY®\; (ponesimod) in the U.S. | \n'); } if (allow) { document.write('
| 1/25 - 1:09 PM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal | \n'); } if (allow) { document.write('
| 1/23 - 9:16 AM \; \; | \n'); } if (allow) { document.write('Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S | \n'); } if (allow) { document.write('
 | |
| more news | \n'); } if (allow) { document.write('\n'); } if (allow) { document.write(' |
If you reached this page'+
' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+
' paying client. For pricing information please visit our products page, email '+
' services@tickertech.com, or give us a call at 1-866-515-2082.'+
' '+
'